Cold Chain Products Market is Expected to Reach $711 million | MarketsandMarkets

Cold Chain Products market in terms of revenue was estimated to be worth $569 million in 2022 and is poised to reach $711 million by 2027, growing at a CAGR of 4.5% from 2022 to 2027 according to a latest report published by MarketsandMarkets™. Factors like Rising use of immunoglobulins and other plasma products in a range of therapeutic areas and Increasing demand for Plasma-derived medicinal products are driving the growth of the Cold Chain Products Market for Plasma Fractionation.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=159802939&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Major Cold Chain Products market players covered in the report, such as:

B Medical Systems (US)
Blue Star Limited (India)
Thermo Fisher Scientific (US)
Godrej and Boyce Manufacturing Co. Ltd. (India)
Haier Biomedical (China)
Eppendorf SE (Germany)
Avantor
Inc. (US)
Biolife Solutions Inc. (US)
Helmer Scientific Inc. (US)
and Among Others

Buy Cold Chain Products Market Report (200 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=159802939&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

The research report categorizes Cold Chain Products Market into the following segments and sub-segments:

By Type

Ultra-low temperature freezer
Plasma freezer
Temperature monitoring devices
Plasma contact shock freezer
Blood transport boxes
Ice-lined refrigerator
Others

By End User

Blood collection centers and blood component providers
Hospitals and transfusion centers
Clinical research laboratories
Others

By Country

North America
US
Canada
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Australia
Japan
India
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East and Africa
Turkey
Rest of MEA

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=159802939&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

The cold chain products market for plasma fractionation involves various key stakeholders who play critical roles in ensuring the safe and efficient transportation and storage of plasma-derived products. These stakeholders include:

Plasma Fractionation Companies: These are the companies involved in the process of fractionating plasma to separate and purify different blood components, such as albumin, immunoglobulins, clotting factors, and other plasma proteins. They are responsible for ensuring the quality and safety of the fractionated products and packaging them appropriately for transportation.

Pharmaceutical Companies: Pharmaceutical companies are the primary manufacturers and distributors of plasma-derived products. They rely on the cold chain infrastructure to transport their products from manufacturing facilities to distribution centers and ultimately to healthcare providers. These companies work closely with plasma fractionation companies to ensure the timely and secure delivery of their products while maintaining their integrity and efficacy.

Cold Chain Logistics Providers: Cold chain logistics providers specialize in the transportation and storage of temperature-sensitive products. They have the expertise and infrastructure to handle and maintain the required temperature conditions throughout the supply chain. These providers ensure that plasma-derived products are stored and transported within the specified temperature range to prevent degradation or spoilage.

Healthcare Facilities: Hospitals, clinics, and other healthcare facilities are the end-users of plasma-derived products. They rely on the cold chain system to receive these products in a timely and secure manner. Healthcare facilities also play a crucial role in proper storage and handling of these products once they are delivered, ensuring their availability for patient treatment.

Regulatory Authorities: Regulatory authorities, such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe, establish guidelines and regulations for the storage, transportation, and handling of plasma-derived products. These authorities monitor and enforce compliance to ensure the safety and quality of these products throughout the cold chain.

Patients: Ultimately, patients are the beneficiaries of the cold chain products for plasma fractionation. These products are used for various therapeutic purposes, including treatment of immune deficiencies, coagulation disorders, and other medical conditions. Ensuring the integrity of the cold chain is crucial to guarantee that patients receive safe and effective plasma-derived products.

Overall, collaboration and coordination among these key stakeholders are essential to maintain the integrity of the cold chain for plasma fractionation products, ensuring their availability and safety for patients in need.

Cold Chain Products Market Frequently Asked Questions (FAQs):

Q1. What is the total market value of Cold Chain Products Market report?

Q2. Which are the top companies holding the market share in Cold Chain Products Market?

Q3. Which are the largest regions for this Market?

Q4. What is the leading technology of Cold Chain Products Market?

Q5. What are the major drivers for this specific Market?

Q6. What are the upcoming key trends in the Cold Chain Products Market report?

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=159802939&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.